New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important ...

On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the ...

On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...

People who lost significant weight while taking Ozempic, Wegovy, Mounjaro, or Saxenda had sharply lower risks of major ...

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, ...

New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following ...

New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following ...

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that ...

This continuing education course details the role of GLP-1 injectables in managing chronic conditions and overweight/obesity, ...

Research shows sick leave among patients prescribed GLP-1 injections over nine-month period reduced by 50% ...